This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (NCT04505774), a randomized phase 4 study. The primary outcome is 21 Day Organ Support (Respiratory or Vasopressor) Free Days.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT04505774 |
| Phase | Phase 4 |
| Condition | Covid19 |
| Allocation | Randomized |
| Design model | Sequential |
| Masking | None (open label) |
| Enrollment | 3591 |
| Arms in the primary outcome | 8 |
| Lead sponsor | Matthew Neal MD |
| Results posted | Yes |
2. Clinical Question
Population
Hospitalized adults with COVID-19 were the trial population described in the registry. The record identifies the condition as Covid19 and describes the study as enrolling COVID-19-positive inpatients. It does not report further eligibility details, such as how illness severity was defined for each analysis or the demographic and clinical characteristics of participants in the posted results.
Intervention
The platform evaluated antithrombotic and additional strategies. The posted arms include therapeutic-dose anticoagulation, prophylactic-dose anticoagulation, combinations of those approaches with a P2Y12 inhibitor, standard care with an SGLT2 inhibitor, and standard care with crizanlizumab. The arm descriptions indicate that some strategies were restricted to moderate or severe illness, but full eligibility and treatment-administration details are not reported in the registry record.
Comparator
Comparators depended on the platform arm. The registry lists standard-of-care groups alongside the SGLT2 inhibitor and crizanlizumab comparisons, and lists prophylactic-dose anticoagulation as a comparison for therapeutic-dose anticoagulation. The P2Y12 arms also have a reported comparison with one another. These comparisons should be read as specific to the posted arm pair, not as one common comparison across the entire platform.
Primary question
The primary outcome was median days alive and free of respiratory or vasopressor organ support through the first 21 days after enrollment, with death during the index hospitalization assigned a value of -1 days. The registry reports the outcome by arm and gives test results for listed arm pairs. It does not report a single overall platform-wide effect estimate. The statistical question is therefore whether the posted arm-level summaries and comparisons provide evidence of differences in this defined outcome, and how much uncertainty can be assessed from the limited estimates and intervals in the record.
3. Trial Design
NCT04505774, titled “Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE,” is described as a multicenter, adaptive, randomized controlled platform trial. The registry lists the phase as PHASE4, the allocation as randomized, the masking as none, and the model as sequential. The trial is marked completed. Its start date is 2020-09-04, and its primary completion date is 2023-08-31. Enrollment is listed as 3591.
The platform evaluated several strategies rather than one intervention against one fixed comparator throughout. The posted treatment groups include therapeutic-dose and prophylactic-dose anticoagulation, each with or without a P2Y12 inhibitor in designated arms, as well as standard care with an SGLT2 inhibitor or crizanlizumab. Arm descriptions state that some groups enrolled moderate illness patients only and others severe illness patients only. They also record that enrollment or an arm was ended at different points, including decisions attributed to the DSMB. Those changes are part of the platform’s registry history, but the record does not fully describe the allocation process at each stage or how each analysis accounted for the platform’s changing membership.
The primary outcome is a median, not a mean: days alive and free of specified organ support through the stated follow-up period. The registry reports arm-level sample sizes, medians, and interquartile ranges, plus t-test results for four listed pairwise comparisons. It also lists secondary outcomes and analyses. The full statistical analysis plan, details of interim decision rules, and the analysis populations for each result are not reported in the registry record. Accordingly, the posted results support a description of the trial’s recorded comparisons, but not a reconstruction of every design or analysis decision.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Only the first 6 of 8 groups are shown.
Overall Study
| Stage | Therapeutic Dose Anticoagulation | Prophylactic Dose Anticoagulation | Therapeutic Dose Anticoagulation + P2Y12 Inhibitor | Prophylactic Dose Anticoagulation + P2Y12 Inhibitor | Standard of Care + SGLT2 Inhibitor | Standard of Care (SGLT2) |
|---|---|---|---|---|---|---|
| STARTED | 569 | 514 | 772 | 739 | 287 | 288 |
| COMPLETED | 565 | 511 | 766 | 735 | 280 | 287 |
| NOT COMPLETED | 4 | 3 | 6 | 4 | 7 | 1 |
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
Only the first 6 of 9 groups are shown.
| Characteristic | Unit | Therapeutic Dose Anticoagulation | Prophylactic Dose Anticoagulation | Therapeutic Dose Anticoagulation + P2Y12 Inhibitor | Prophylactic Dose Anticoagulation + P2Y12 Inhibitor | Standard of Care + SGLT2 Inhibitor | Standard of Care (SGLT2) |
|---|---|---|---|---|---|---|---|
| Participants analysed | 569 | 514 | 772 | 739 | 287 | 288 | |
| Age, Categorical: <=18 years | Participants | 0 | 0 | 0 | 2 | 0 | 0 |
| Age, Categorical: Between 18 and 65 years | Participants | 336 | 300 | 575 | 559 | 57 | 75 |
| Age, Categorical: >=65 years | Participants | 233 | 214 | 197 | 178 | 230 | 213 |
| Sex: Female, Male: Female | Participants | 232 | 222 | 295 | 283 | 119 | 123 |
| Sex: Female, Male: Male | Participants | 337 | 292 | 477 | 456 | 168 | 165 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 12 | 7 | 13 | 17 | 2 | 2 |
| Race (NIH/OMB): Asian | Participants | 25 | 23 | 20 | 28 | 7 | 14 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 1 | 2 | 8 | 8 | 1 | 0 |
| Race (NIH/OMB): Black or African American | Participants | 136 | 89 | 169 | 159 | 37 | 32 |
| Race (NIH/OMB): White | Participants | 292 | 282 | 455 | 425 | 210 | 201 |
| Race (NIH/OMB): More than one race | Participants | 1 | 1 | 5 | 6 | 1 | 0 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 102 | 110 | 102 | 96 | 29 | 39 |
| Region of Enrollment: United States | participants | 504 | 450 | 574 | 541 | 217 | 219 |
| Region of Enrollment: Brazil | participants | 0 | 0 | 88 | 90 | 2 | 3 |
| Region of Enrollment: Italy | participants | 0 | 0 | 19 | 18 | 2 | 2 |
| Region of Enrollment: Spain | participants | 65 | 64 | 89 | 86 | 63 | 63 |
| Region of Enrollment: Mexico | participants | 0 | 0 | 2 | 4 | 3 | 1 |
6. Primary Endpoint
The registry lists the primary outcome as 21 Day Organ Support (Respiratory or Vasopressor) Free Days, measured over 21 days from study enrollment.
| Element | Registry entry |
|---|---|
| Result type | Median |
| Measure of spread | Inter-Quartile Range |
| Unit | days |
| Endpoint classification | Time-to-Event Analysis |
The primary endpoint, “21 Day Organ Support (Respiratory or Vasopressor) Free Days,” counts days alive and free of organ support through the first 21 days after trial enrollment. The registry defines organ support to include non-invasive mechanical ventilation, high-flow nasal cannula oxygen, mechanical ventilation, or vasopressor therapy. Death at any time during the index hospitalization is assigned -1 days. This definition combines survival and time without specified support into one outcome: a lower value can reflect death, more organ-support use, or both, rather than a single clinical event.
The record describes the endpoint as a median with an interquartile range. The median gives the midpoint of the observed distribution, while the interquartile range describes the middle portion of that distribution. These summaries can be useful when outcomes are skewed or contain many observations at a boundary, because they do not depend on the mean alone. The endpoint’s interpretation requires care: the registry notes that the measure was designed to exceed day 21 on the interquartile range because baseline day 0 is included in the design. Thus a posted median of 22 is not, by itself, evidence that participants were observed beyond the stated follow-up period. It reflects the registry’s endpoint construction.
Using an outcome that incorporates death and organ support can provide a compact view of patients’ clinical course, but it also makes the underlying components less visible. The record does not report component-specific primary results or a distribution plot in text. Interpretation should therefore stay with the defined composite and its reported summaries rather than attribute a difference to survival or any particular type of support.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
Across the posted primary endpoint arms, the median is 22 days for therapeutic-dose anticoagulation, prophylactic-dose anticoagulation, standard care with an SGLT2 inhibitor, standard care in the SGLT2 comparison, standard care with crizanlizumab, and standard care in the crizanlizumab comparison. The median is 17 days for both P2Y12-inhibitor combination arms. The interquartile ranges differ across these groups: the two anticoagulation-only arms extend from 18 to 22 days and from 17 to 22 days, while the P2Y12 combination arms extend from 1 to 21 days and from 0 to 21 days. The posted standard-care and add-on arms have ranges of 22 to 22 days.
These descriptive summaries do not establish that one strategy caused a better or worse outcome. A median is only one feature of the outcome distribution, and the registry does not provide primary-outcome effect estimates or confidence intervals for the listed pairwise comparisons. It reports two-sided t-test results for the therapeutic-dose versus prophylactic-dose comparison, the two P2Y12 arms, the SGLT2 inhibitor comparison, and the crizanlizumab comparison. Without effect estimates and intervals, the magnitude and precision of differences in the primary outcome cannot be evaluated from those tests alone. The record also does not explain how the t-tests were applied to this median-and-interquartile-range endpoint.
Several groups have the same reported median, but identical medians do not prove that their full outcome distributions are identical. Conversely, the lower medians in the P2Y12 arms do not on their own establish a treatment effect. The ranges indicate that the observed distributions are not summarized fully by the medians, and the record does not supply enough detail to determine the roles of severity, enrollment period, missing observations, or other factors in these patterns.
The trial was adaptive and sequential, and arm descriptions record that groups were ended or stopped at different times. This context matters because comparisons within a platform may involve different eligible populations or periods. The registry gives no complete account of those details or a multiplicity strategy. The most defensible reading is descriptive: the primary endpoint summaries vary across the recorded arms, while the information needed to quantify primary-outcome differences and their uncertainty is not reported in the registry record.
9. Statistical Methods Explained
What does the median describe?
For an outcome distribution, the median is its central ranked value: half of the observations fall at or below it and half at or above it, subject to the way tied values are handled. It is not the average. A median is often useful when the distribution is asymmetric or includes many observations at the same value. The interquartile range gives the lower and upper quartiles and describes the spread of the middle half of the observations. It does not show every feature of the distribution, and it is not a confidence interval for the median.
Here the primary outcome is a count of days, with death assigned -1 days and baseline day 0 included. The registry explicitly notes that this construction can produce an interquartile range extending beyond day 21. The 22-day medians and ranges at 22 should therefore be understood in light of that coding convention, not interpreted as a longer follow-up window. The record does not provide a textual description of how tied or incomplete endpoint values were handled.
What is a confidence interval?
In general, a confidence interval expresses the precision of an estimated quantity under the assumptions of the statistical method. A narrow interval indicates greater precision than a wide interval, while an interval that includes values on both sides of a null or no-difference value may be compatible with a range of effects. An interval does not give the probability that the true effect lies within the particular reported bounds. No confidence intervals are reported for the primary endpoint comparisons in the registry record, so the precision of those comparisons cannot be judged from the listed test results alone.
What do the reported tests contribute?
The registry identifies the primary comparisons as two-sided t-tests. In general, a two-sided test evaluates departures in either direction, rather than prespecifying that only an increase or only a decrease matters. A p-value is a measure of how incompatible the observed data are with a specified null model and its assumptions; it is not the probability that the null hypothesis is true, nor is it an estimate of clinical importance. For these primary results, the record lists p-values but no comparison-specific effect estimates or intervals. It does not report the detailed test specification, adjustment for covariates, or a reason for using the stated test with an endpoint summarized by medians and interquartile ranges.
The registry also records chi-squared tests for some secondary comparisons. In general, a chi-squared test assesses whether categorical outcome distributions differ between groups under the test’s assumptions. It does not, by itself, quantify the size or precision of a difference. The registry’s recalculated binary comparisons use unadjusted risk differences and intervals from posted counts. Such calculations can provide an interpretable descriptive contrast, but they are not replacements for the sponsor’s prespecified analysis. The full statistical analysis plan is not reported in the registry record.
Why can over-dispersion matter?
In general, over-dispersion occurs when observed variability is greater than a model assumes. A model that understates variability can produce intervals that are too narrow and tests that appear more decisive than warranted. This concept is relevant to count outcomes and other data whose variability may not match a simple model. The registry does not report an over-dispersion assessment or a model-based analysis for the primary endpoint, so no conclusion about whether over-dispersion was present can be drawn for this trial.
How should the recalculations be read?
The recalculated binary estimates are simple, unadjusted contrasts derived from the posted summary counts. A risk difference compares the event proportions in the two groups; a risk ratio compares those proportions as a ratio. In general, the risk difference is expressed on an absolute scale, while the risk ratio is a relative scale. The estimates do not account for covariates, platform adaptations, missing data, or any analysis adjustments unless those are explicitly part of the calculation. Their confidence intervals describe uncertainty under the calculation’s assumptions, not every source of uncertainty in the trial.
The sample-size figures are planning illustrations calculated from the observed effect under the stated assumptions: two-sided significance level 0.05, equal allocation, and a normal approximation. The illustrations vary the effect to detect as a fraction of the observed effect and report participants per arm for the stated power targets. They are not observed power, do not reveal the original sample-size justification, and should not be treated as the trial’s actual design targets. The planning assumptions do not establish that a future study would reproduce the observed effect. The registry record does not report the trial’s original sample-size justification.
Finally, a statistical test result is only one part of interpretation. The arm-level summaries, effect size, interval, outcome definition, analysis population, and design context all matter. The registry does not report all of these elements for every endpoint. Where estimates or analysis details are absent, uncertainty should be described as unresolved rather than filled in by assumptions.
10. Analyses Reported by the Sponsor
| Method | Estimate | 95% CI | P-value |
|---|---|---|---|
| t-test, 2 sided | not reported | 0.678 | |
| t-test, 2 sided | not reported | 0.629 | |
| t-test, 2 sided | not reported | 0.686 | |
| t-test, 2 sided | not reported | 0.135 |
The registry’s own primary analyses are listed as two-sided t-tests for four arm pairs. They are the sponsor-reported statistical results for those comparisons. The record does not give primary-outcome effect estimates or confidence intervals alongside the tests, so the size and precision of any difference cannot be reconstructed from the reported p-values alone. The posted arm medians and interquartile ranges provide descriptive context, but they do not substitute for an estimate of the between-group effect.
For selected secondary binary outcomes, recalculated estimates use unadjusted contrasts from the posted counts. These calculations are useful as a transparent description of the counts and their uncertainty, but they do not necessarily reproduce the sponsor’s analyses. For example, the recalculated contrasts for some outcomes use the standard-care-plus-SGLT2-inhibitor group as a comparator, while the registry’s listed tests for those outcomes compare other specified arm pairs. The comparator and estimand must therefore be checked before comparing a recalculated result with a sponsor-reported test.
The registry record does not report enough information to establish whether the recalculations align with every planned analysis choice, including analysis populations, adjustments, missing-data handling, or the platform’s adaptive features. The sponsor’s own reported analyses remain the record of the sponsor’s analysis; recalculated values are supplementary unadjusted summaries, not a replacement or a correction. The discrepancy flag is false, but the lack of full analysis details still limits direct reconciliation.
11. Multiplicity, Missing Data and Analysis Populations
The registry describes an adaptive, sequential platform and lists many outcomes and analyses. That design context makes multiplicity important: when multiple interventions, outcomes, and comparisons are examined, the chance of at least one apparently notable result can increase. In general, a prespecified testing hierarchy, adjustment procedure, or other explicit strategy can help readers understand how the total evidence was assessed. The multiplicity strategy is not reported in the registry record. The record also does not state which secondary outcomes were intended to be confirmatory or how interim decisions were incorporated into final inference.
The arm descriptions record that several arms were stopped or ended at different times, sometimes with a DSMB decision noted. However, the registry does not report the interim analysis schedule, stopping boundaries, monitoring rules, or the statistical treatment of those decisions. The reasons and dates recorded for arm changes do not, by themselves, reveal whether or how repeated testing was controlled. The complete protocol and statistical analysis plan are not reported in the registry record.
Missing-data methods and analysis populations are also not reported in the registry record. There is no detailed account of how participants without endpoint measurements were handled, whether analyses followed intention-to-treat principles, or whether exclusions differed by outcome or arm. The displayed sample sizes vary across outcomes, but the record does not explain every variation. These gaps matter because missingness and population definitions can affect both group summaries and comparisons.
The registry reports randomized allocation, but randomization alone does not resolve these reporting questions. Readers need to know which randomized participants contributed to each analysis, how incomplete outcomes were treated, and whether the analysis followed the prespecified strategy. Without that information, the results can be described as posted, but their sensitivity to missing data, interim monitoring, and multiplicity cannot be assessed. These uncertainties should not be filled with assumptions about standard practice.
12. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Therapeutic Dose Anticoagulation | 46 | 569 | 8.1% |
| Prophylactic Dose Anticoagulation | 57 | 514 | 11.1% |
| Therapeutic Dose Anticoagulation + P2Y12 Inhibitor | 151 | 772 | 19.6% |
| Prophylactic Dose Anticoagulation + P2Y12 Inhibitor | 133 | 739 | 18.0% |
| Standard of Care + SGLT2 Inhibitor | 20 | 287 | 7.0% |
| Standard of Care (sglt2) | 33 | 288 | 11.5% |
| Standard of Care + Crizanlizumab | 24 | 211 | 11.4% |
| Standard of Care (Criza) | 28 | 211 | 13.3% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| Therapeutic Dose Anticoagulation | 69 of 569 |
| Prophylactic Dose Anticoagulation | 65 of 514 |
| Therapeutic Dose Anticoagulation + P2Y12 Inhibitor | 147 of 772 |
| Prophylactic Dose Anticoagulation + P2Y12 Inhibitor | 149 of 739 |
| Standard of Care + SGLT2 Inhibitor | 37 of 287 |
| Standard of Care (sglt2) | 42 of 288 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 0% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Therapeutic Dose Anticoagulation | 0 of 0 |
| Prophylactic Dose Anticoagulation | 0 of 0 |
| Therapeutic Dose Anticoagulation + P2Y12 Inhibitor | 0 of 0 |
| Prophylactic Dose Anticoagulation + P2Y12 Inhibitor | 0 of 0 |
| Standard of Care + SGLT2 Inhibitor | 0 of 0 |
| Standard of Care (sglt2) | 0 of 0 |
Most frequent serious adverse event terms
| Event term | Organ system | Therapeutic Dose Anticoagulation | Prophylactic Dose Anticoagulation | Therapeutic Dose Anticoagulation + P2Y12 Inhibitor | Prophylactic Dose Anticoagulation + P2Y12 Inhibitor | Standard of Care + SGLT2 Inhibitor | Standard of Care (sglt2) |
|---|---|---|---|---|---|---|---|
| Venus thrombosis | Vascular disorders | 10 of 569 | 14 of 514 | 47 of 772 | 47 of 739 | 1 of 287 | 5 of 288 |
| Pulmonary Embolism | Respiratory, thoracic and mediastinal disorders | 10 of 569 | 18 of 514 | 41 of 772 | 26 of 739 | 2 of 287 | 3 of 288 |
| other | Injury, poisoning and procedural complications | 2 of 569 | 3 of 514 | 24 of 772 | 34 of 739 | 9 of 287 | 8 of 288 |
| major bleeding | Vascular disorders | 13 of 569 | 8 of 514 | 21 of 772 | 17 of 739 | 4 of 287 | 3 of 288 |
| ischemmic stroke | Vascular disorders | 3 of 569 | 3 of 514 | 11 of 772 | 3 of 739 | 0 of 287 | 1 of 288 |
| myocardial infarction | Cardiac disorders | 2 of 569 | 2 of 514 | 7 of 772 | 4 of 739 | 0 of 287 | 1 of 288 |
| acute kidney injury | Renal and urinary disorders | 0 of 569 | 0 of 514 | 3 of 772 | 0 of 739 | 4 of 287 | 7 of 288 |
| heparin induced thrombocytopenia | Injury, poisoning and procedural complications | 2 of 569 | 3 of 514 | 3 of 772 | 3 of 739 | 0 of 287 | 0 of 288 |
| Deep Vein Thrombosis | Vascular disorders | 1 of 569 | 2 of 514 | 1 of 772 | 0 of 739 | 0 of 287 | 3 of 288 |
| arterial thromboembolic event | Vascular disorders | 2 of 569 | 2 of 514 | 0 of 772 | 2 of 739 | 0 of 287 | 1 of 288 |
Serious events with the highest arm-level rate: venus thrombosis (6.4%), pulmonary embolism (5.3%), acute kidney injury (4.7%), other (4.6%), major bleeding (2.8%).
The safety record reports serious-event counts for each listed group, including participants at risk and participants affected, and also reports deaths. These are descriptive registry figures. They do not by themselves establish that an event was caused by a study intervention, nor do they provide a controlled causal comparison. The record does not give detailed event definitions, severity grading, follow-up completeness, or a formal comparative safety analysis for these figures.
The listed serious-event terms include Venus thrombosis at 6.4%, pulmonary embolism at 5.3%, acute kidney injury at 4.7%, other at 4.6%, major bleeding at 2.8%, and ischemic stroke at 1.4% (the registry spelling for ischemic stroke is “ischemmic stroke”). Those percentages are reported terms, not newly calculated rates. The record does not specify in this summary how the percentage denominator was defined for each term, so they should not be compared as though their denominators and ascertainment were necessarily identical.
Group-level serious-event denominators differ from some outcome-specific sample sizes in the registry. Without an explanation of the populations and follow-up used for each safety measure, direct comparisons across the safety and efficacy summaries are limited. These figures are useful for describing what was recorded, but not for making treatment recommendations or attributing harm or benefit.
13. What the Result Does, and Does Not, Mean
The posted results describe a complex randomized platform trial in hospitalized adults with COVID-19. For the primary endpoint, several arms have a median of 22 days and both P2Y12 combination arms have a median of 17 days. The interquartile ranges vary by group, and the registry notes that the endpoint’s day-0 convention can produce values extending beyond day 21. These summaries characterize the recorded endpoint; they do not identify which component of the composite—death or organ-support use—accounts for the observed distributions.
The registry reports test results for specified arm pairs, but it does not report primary-outcome effect estimates or confidence intervals. Without those quantities and further analysis details, the magnitude and precision of the primary comparisons cannot be determined from the posted record. A p-value alone does not establish the size, importance, or cause of a difference. Nor does an identical median mean that all aspects of the groups’ outcomes were identical.
Secondary results add information about other outcomes, but their different definitions, timeframes, and comparison groups prevent them from serving as a single, straightforward verdict on the primary result. The record does not report a multiplicity strategy, complete missing-data methods, or the analysis populations. Because the trial was adaptive and sequential, the arm history also needs to be considered when interpreting comparisons; the registry does not provide enough detail to resolve every design implication.
Overall, the record supports a careful description of posted group summaries and selected tests, not a broad conclusion about all strategies or all hospitalized people with COVID-19. The results do not establish that any treatment works or does not work. They also do not justify individual medical decisions. The statistically appropriate conclusion is bounded by the reported endpoints, arm-specific comparisons, and substantial information not reported in the registry record.
14. Why This Trial Matters Statistically
This trial is statistically notable because it uses an adaptive, sequential platform to evaluate multiple strategies within a randomized framework. Such platforms can organize related comparisons under a shared trial structure, but their interpretation depends on transparent reporting of how arms open and close, which participants are eligible for each comparison, and how interim decisions enter the analysis. The registry gives some arm-history details, while leaving important parts of that analytical account unreported.
The primary endpoint also illustrates why outcome definitions matter. It combines survival and freedom from respiratory or vasopressor support, assigns death a value of -1 days, and includes baseline day 0 in a way that can place values beyond the nominal 21-day window. A reader who sees a median of 22 without that definition could misunderstand what the number represents. Clear endpoint construction is essential to comparing summaries correctly.
The record further shows why descriptive summaries and inferential results should be separated. Medians and interquartile ranges reveal patterns in observed groups, while tests and effect estimates address comparisons under specified assumptions. Without primary effect estimates and confidence intervals, the precision of the registered tests is difficult to assess. Secondary recalculations can clarify unadjusted contrasts, but they answer only the comparison defined by their selected arms and counts.
Finally, the trial’s many outcomes and analyses make multiplicity and analysis transparency central statistical issues. The registry offers a broad set of results, yet does not report the full plan for multiplicity, missing observations, or analysis populations. This makes the record useful for describing what was posted while also demonstrating why complete reporting is needed to evaluate a complex adaptive study.
15. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
Several limitations are specific to the posted record for this trial. First, the primary outcome is reported through medians and interquartile ranges, while the registry lists t-tests for the pairwise analyses. The record does not provide the comparison estimates, confidence intervals, or detailed test specification needed to understand how those tests relate to the distributional summaries.
Second, the platform includes multiple treatments and comparison groups with different illness-severity eligibility and arm histories. Arm descriptions record that some groups stopped or ended at different times. The registry does not provide enough detail to assess how calendar period, eligibility, platform adaptations, or changes in available comparisons were handled in each analysis. Comparisons should not be assumed to represent one common population or one common comparator.
Third, the posted counts for “Major Thrombotic Event or in Hospital Death” include 450 events among 450 participants in the therapeutic-dose anticoagulation arm and 462 among 463 in the prophylactic-dose arm. These figures are markedly different in form from the counts in other arms for the same outcome. The record does not explain this pattern. It warrants verification before those specific values or recalculations based on them are interpreted as event frequencies.
Finally, the record does not report the full statistical analysis plan, multiplicity method, missing-data handling, or analysis populations. Safety denominators also differ from some endpoint-specific sample sizes without a full explanation. These gaps limit assessment of precision, bias, and comparability. They do not show that the results are invalid, but they constrain what can responsibly be concluded from the registry alone.
16. Related Tutorials
17. Related Statistical Calculators
18. Sources
- ClinicalTrials.gov: Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE — NCT04505774.
- Registry record last updated 2024-12-30; status last verified 2024-12.
- Results first posted 2024-12-30.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
19. Record Summary
NCT04505774 is a completed, randomized, open-label, multicenter, adaptive sequential platform trial in hospitalized adults with COVID-19. The registry lists enrollment of 3591 and a primary endpoint of median organ-support-free days through the first 21 days after enrollment, with death during the index hospitalization assigned -1 days.
The primary endpoint medians are 22 days in several posted arms and 17 days in the two P2Y12 combination arms. The record reports two-sided t-tests for four primary arm pairs, but does not provide primary comparison effect estimates or confidence intervals. Secondary results cover mortality and other clinical outcomes, while safety entries report serious events and deaths by group.
The registry does not report the complete statistical analysis plan, multiplicity strategy, missing-data methods, or analysis populations. The posted results can be described by arm, but uncertainty and causal interpretation are limited by those omissions and by the platform’s changing arm structure.